Welcome to CDC Stacks | Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells - 42717 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells
  • Published Date:
    Sep 22 2016
  • Source:
    Atherosclerosis. 254:59-66.

Public Access Version Available on: November 01, 2017 information icon
Please check back on the date listed above.
  • Pubmed ID:
  • Pubmed Central ID:
  • Description:
    Background and aims

    Obstructive sleep apnea (OSA) is characterized by intermittent airway obstruction and systemic hypoxia during sleep, which can contribute to an increase in reactive oxygen species, vascular remodeling, vasoconstriction and ultimately cardiovascular disease. Continuous positive airway pressure (CPAP) is a clinical therapy that maintains airway patency and mitigates several symptoms of OSA. However, it is currently unknown whether CPAP therapy also reduces the overall inflammatory potential in the circulation; to address this in an unbiased manner, we applied a novel endothelial biosensor approach, the serum cumulative inflammatory potential (SCIP) assay.


    We studied healthy controls (n=7), OSA subjects receiving no treatment, (OSA controls) (n=7) and OSA subjects receiving CPAP for 3 months (n=8). Serum was obtained from OSA subjects before and after CPAP or no treatment. A battery of quantitative and functional assays was performed to assess the serum inflammatory potential, in terms of endothelial responses. For the SCIP assay, human coronary artery endothelial cells (hCAECs) were incubated with 5% serum in media from individual subjects for 4 h. qPCR was performed to assess endothelial inflammatory transcript (ICAM-1, VCAM-1, IL-8, P-selectin, CCL5, and CXCL12) responses to serum. Additionally, transendothelial resistance was measured in serum-incubated hCAECs following leukocyte challenge.


    hCAECs exhibited significant increases in VCAM-1, ICAM-1, IL-8 and P-selectin mRNA when incubated with serum from OSA patients compared to serum from healthy control subjects. Furthermore, compared to no treatment, serum from CPAP-treated individuals was less potent at inducing inflammatory gene expression in the SCIP assay. Similarly, in a leukocyte adhesion assay, naïve cells treated with serum from patients who received CPAP exhibited improved endothelial barrier function than cells treated with OSA control serum.


    OSA results in greater serum inflammatory potential, thereby driving endothelial activation and dysfunction.

  • Document Type:
  • Collection(s):
  • Funding:
    R01 HL080105/HL/NHLBI NIH HHS/United States
    R01 OH010828/OH/NIOSH CDC HHS/United States
    R01 ES014639/ES/NIEHS NIH HHS/United States
    R01 HL128970/HL/NHLBI NIH HHS/United States
    K12 GM088021/GM/NIGMS NIH HHS/United States
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: